share_log

康健國際醫療：內部控制跟進審閱

TOWN HEALTH: INTERNAL CONTROL FOLLOW-UP REVIEW

香港交易所 ·  Mar 25 09:59
Summary by Moomoo AI
康健國際醫療集團有限公司（「本公司」）於2024年3月25日宣布，根據2021年2月26日的公告，公司股份復牌所需的所有條件已經達成。這包括了本公司對內部控制報告中提出的所有改進建議的實施，以及由顧問進行的跟進審閱。該顧問已向公司及證監會執行人員提交了跟進審閱報告，並認為沒有發現重大內部控制缺陷。本公司已按照顧問在內部控制報告中設定的目標完成日期前實施了所有改進建議，並已完成截至2021年10月31日的跟進審閱。本公司的執行董事包括蔡加讚先生（主席兼行政總裁）、霍兆榮醫生、張霄雪女士及劉詩音先生；非執行董事包括李蕙苓女士、劉淑卿女士、劉陽先生及張蕾娣女士；獨立非執行董事則有于學忠先生、徐衛國博士、韓文欣先生、陳偉根先生、張加銘先生及崔永昌先生。
康健國際醫療集團有限公司（「本公司」）於2024年3月25日宣布，根據2021年2月26日的公告，公司股份復牌所需的所有條件已經達成。這包括了本公司對內部控制報告中提出的所有改進建議的實施，以及由顧問進行的跟進審閱。該顧問已向公司及證監會執行人員提交了跟進審閱報告，並認為沒有發現重大內部控制缺陷。本公司已按照顧問在內部控制報告中設定的目標完成日期前實施了所有改進建議，並已完成截至2021年10月31日的跟進審閱。本公司的執行董事包括蔡加讚先生（主席兼行政總裁）、霍兆榮醫生、張霄雪女士及劉詩音先生；非執行董事包括李蕙苓女士、劉淑卿女士、劉陽先生及張蕾娣女士；獨立非執行董事則有于學忠先生、徐衛國博士、韓文欣先生、陳偉根先生、張加銘先生及崔永昌先生。
HEALTH INTERNATIONAL MEDICAL GROUP LIMITED (THE “COMPANY”) ANNOUNCED ON MARCH 25, 2024 THAT ALL CONDITIONS REQUIRED FOR THE COMPANY'S SHARE REAUTHORIZATION HAVE BEEN MET, PURSUANT TO THE ANNOUNCEMENT DATED FEBRUARY 26, 2021. This includes implementation of all improvement recommendations made by the Company in the Internal Control Report, as well as follow-up reviews by consultants. The consultant has submitted a follow-up review report to the Company and Securities and Exchange Commission executives and considers that no significant internal control deficiencies have been identified. The Company has implemented all improvement recommendations prior to the target completion date set by the consultant in the Internal Control Report and completed the follow-up review as of October 31, 2021. The Executive Directors of the Company include...Show More
HEALTH INTERNATIONAL MEDICAL GROUP LIMITED (THE “COMPANY”) ANNOUNCED ON MARCH 25, 2024 THAT ALL CONDITIONS REQUIRED FOR THE COMPANY'S SHARE REAUTHORIZATION HAVE BEEN MET, PURSUANT TO THE ANNOUNCEMENT DATED FEBRUARY 26, 2021. This includes implementation of all improvement recommendations made by the Company in the Internal Control Report, as well as follow-up reviews by consultants. The consultant has submitted a follow-up review report to the Company and Securities and Exchange Commission executives and considers that no significant internal control deficiencies have been identified. The Company has implemented all improvement recommendations prior to the target completion date set by the consultant in the Internal Control Report and completed the follow-up review as of October 31, 2021. The Executive Directors of the Company include Mr. Cai Ka-san (Chairman and Chief Executive Officer), Dr. Ho Siu-wing, Ms. Zhang Xiao Xue and Mr. Liu Shiyin; Non-Executive Directors include Ms. Lee Hui-ling, Ms. Liu Shu-qing, Mr. Liu Yang and Ms. Zhang Lei Tai; Independent Non-Executive Directors include Mr. Yue Chung, Dr. Xu Wei Guo, Mr. Korea Mr. Wen Shin, Mr. Chan Wai-gan, Mr. Cheung Ka Ming and Mr. Choi Wing Cheong.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more